GlassScriptPhysician profile
Masoud Afshar
NPI 1225287378
$8,736.04
in general payments reported to CMS, 2019-2025
34 companies · $1,449 in 2025
The $1,449 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $64.41 · 2021: $970 · 2022: $1,785 · 2023: $1,888 · 2024: $2,149 · 2025: $1,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,425 · Education: $61.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,425.40 |
| Education | $61.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,471.07 | 2022-2025 | Farxiga, Lokelma, Tezspire |
| Bayer Healthcare Pharmaceuticals INC. | $884.59 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $618.77 | 2021-2025 | Lupkynis |
| Amgen INC. | $604.37 | 2019-2025 | Krystexxa, Tavneos |
| Horizon Therapeutics Plc | $581.10 | 2021-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $573.28 | 2022-2025 | Acthar |
| Calliditas Therapeutics US INC. | $430.25 | 2022-2025 | Tarpeyo |
| Ardelyx, INC. | $401.90 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Gastroklenz, INC. Dba Cloudcath | $400.00 | 2022 | |
| Vifor Pharma, INC. | $325.72 | 2019-2024 | Veltassa, Korsuva |
| Alexion Pharmaceuticals, INC. | $287.27 | 2019-2023 | Ultomiris |
| Opko Pharmaceuticals, LLC | $235.49 | 2020-2024 | Rayaldee |
| Glaxosmithkline, LLC. | $223.38 | 2021-2025 | Shingrix, Benlysta |
| Otsuka America Pharmaceutical, INC. | $213.30 | 2019-2025 | Jynarque, Voyxact |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.45 | 2024-2025 | Jardiance |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $179.10 | 2019-2024 | Velphoro |
| Boston Scientific Corporation | $160.24 | 2019-2022 | |
| Novo Nordisk INC | $114.84 | 2022-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $104.51 | 2021-2024 | Jardiance, Zepbound |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.00 | 2019 | |
| Ani Pharmaceuticals, INC. | $90.04 | 2025 | Purified Cortrophin Gel |
| Travere Therapeutics, INC. | $78.82 | 2023-2025 | Filspari |
| Novartis Pharmaceuticals Corporation | $67.27 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $58.05 | 2024-2025 | Amvuttra, Oxlumo |
| Akebia Therapeutics INC | $52.75 | 2019-2025 | Auryxia, Vafseo |
| Mallinckrodt Enterprises LLC | $43.16 | 2019 | |
| Amarin Pharma, INC. | $41.77 | 2021 | |
| Shield Therapeutics INC | $41.49 | 2025 | |
| Bard Peripheral Vascular, INC. | $32.20 | 2019 | |
| Daiichi Sankyo INC. | $28.88 | 2020-2022 | |
| Kyowa Kirin, INC. | $27.52 | 2023 | |
| Sumitomo Pharma America, INC. | $23.80 | 2025 | Gemtesa |
| Abbvie INC. | $21.06 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Masoud Afshar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.